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Immune checkpoint blockade therapies are promising next generation 
immunotherapeutic treatments for cancer. Whilst sequential solid biopsies are an invaluable 
source of prognostic information, they are not feasible for monitoring therapeutic outcomes 
over time. Monitoring soluble immune checkpoint markers expression in body fluids could 
potentially be a better alternative. Current methods (e.g. ELISA) for detecting immune-
checkpoint proteins mostly rely on the use of monoclonal antibodies which are expensive and 
time-consuming to manufacture and isolate. Herein, we report an integrated surface enhanced 
Raman scattering (SERS)-microfluidics device for the detection of immune checkpoint 
proteins which involves the use of i) nano yeast single chain variable fragment (scFv) as a 
promising alternative to monoclonal antibodies providing high stability at relative low-cost 
and simplicity for production, ii) graphene oxide functionalised surface to reduces the bio 
functionalization steps,  thus avoiding the general paradigm of biotin-streptavidin chemistry 
and iii) a microfluidic platform enabling alternating current electrohydrodynamics (ac-EHD) 
induced  nanomixing to enhance the target scFv binding and minimize the non-specific 
interactions. Specific and multiplex detection of immune checkpoint biomarkers is achieved 
by SERS based spectral encoding. Using this platform, we successfully demonstrated the 
detection of clinically relevant soluble immune checkpoints PD-1, PD-L1 and LAG-3 from as 
low as 100 fg/mL of analytes spiked in human serum.   
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1. Introduction:  
Immune checkpoints are the key regulatory part of the immune system by which T-
cells recognise host cells and thereby maintains  homeostasis and prevent autoimmunity 
(Joller et al. 2012; Karin et al. 2006; Sakaguchi 2004). In cancer, tumour cells use this 
molecular mechanism of immune suppression to resist antitumor immune response and 
escape from the cell apoptosis system (Alme et al. 2016; Pardoll 2012; Postow et al. 2015; 
Wherry 2011). For instance, the interaction of the programmed cell death-1 (PD-1) and 
lymphocyte activation gene-3 (LAG-3) receptor of T-cells with the programmed cell death 
ligand-1 (PD-L1) and the major histocompatibility complex (MHC) class II molecules of the 
tumour cells respectively are found to be the most common methods used by tumour cell to 
suppress the T cell activity.(Huang et al. 2015b; Iwai et al. 2002). One strategy to avoid this 
immunosuppression is to selectively inhibit/block the immune checkpoints interactions which 
can restore and promote T-cell survival and proliferation (Nagato et al. 2017). Immune 
checkpoint blockade therapy has therefore been found to be instrumental for the treatment of 
cancer (Anderson et al. 2016; Huang et al. 2015b; Sharma and Allison 2015). However, 
monitoring the therapeutic outcome is still challenging and requires invasive methods. 
Soluble immune checkpoint markers which are released from the tumour/T-cell into the 
circulatory system can provide a possible solution for non-invasive monitoring of the patient 
response towards treatment (Shi et al. 2013). Moreover, not all cancer patients respond to the 
same therapy, as such a multiplex soluble immune checkpoints platform could facilitate 
simultaneous monitoring of multiple immune checkpoints which potentially could suggest 
effective therapy for individual patients (Koyama et al. 2016).  
The detection of immune checkpoint markers in complex samples is currently 
facilitated by specific avidity reagents such as monoclonal antibodies (mAbs) (Scott et al. 
2012). However, the production and isolation of antibodies is laborious and the antibody 
efficacy is often affected by the storage conditions that generally requires refrigeration for 
long time storage(Grewal et al. 2016). Recombinant antibody-like molecules such as single 
chain variable fragment (scFv) have emerged as cost-efficient alternative to monoclonal 
antibodies which could be rapidly isolated from various display technologies such as yeast 
display(Holliger and Hudson 2005). While scFvs shows excellent activity on yeast surfaces, 
they lose their efficacy very often in solution. Our group has recently developed an scFv 
based affinity reagent called nanoyeast scFv (NY-scFv) which addressed these limitations 
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and successfully used as an alternative to monoclonal antibodies in detecting clinically 
relevant biomolecules,(Vaidyanathan et al. 2015; Wang et al. 2014),(Grewal et al. 2015).  
Surface-enhanced Raman scattering (SERS) is an excellent readout technique for 
detecting biomolecules, and have gained wide attention as an alternative to fluorescence 
based immune-platform due to its multiplexing capability and photostability (Huang et al. 
2015a; Laing et al. 2016; Luo et al. 2014; Qian and Nie 2008; Wang et al. 2017). However, 
the major limitations of SERS based immune-platform are the less antibody- target 
interaction due to the slow diffusion of SERS nanoparticles and the high level of nonspecific 
attachment of biomolecules towards the sensor surface. To address this limitation, we have 
recently developed a SERS-microfluidic platform which utilizes alternating current 
electrohydrodynamic (ac-EHD) fluid flow thus avoiding the use of any external pump. This 
ac-EHD induced fluid flow generates a nanoscale shear force at the double layer of the 
sensing electrodes which significantly increases the antibody-target binding and at the same 
time shears off the non-specifically bound molecules from the sensor surface (Kamil Reza et 
al. 2016; Wang et al. 2015). Despite this advantages, this method utilized biotin-streptavidin 
chemistry followed by immune-affinity approach using monoclonal antibody which limits its 
application in clinical settings.  
 Herein, we report a SERS-microfluidic immune checkpoint detection platform that 
utilized graphene oxide (GO) and NY-scFv affinity reagent modified surface 
functionalisation to capture the target molecules. The use of NY-scFv provides several 
advantages over monoclonal antibodies as it is cost effective, easy to manufacture and 
temperature stable for long time. The use of GO functionalisation obviates the need for 
biotin-streptavidin chemistry and thereby provides rapid analysis by reducing the 
functionalisation steps in comparison to the previous methods (Chen et al. 2012; Pumera 
2011; Reza et al. 2015; Wang et al. 2011). The assay also used an ac-EHD induced surface 
shear forces that increases the sensitivity and specificity due to the increase of NY-scFv-
target interaction and removal of the non-specific adsorption of biomolecules towards sensor 
surface. Finally, the detection with SERS provides multiplexing capacity without photo 
bleaching, a common limitation of fluorescence based methods. Using this platform, we show 
that the assay is highly specific in detecting immune checkpoint markers (i.e. PD-1, PD-L1 
and LAG-3) with negligible non-specific signal. We also demonstrate the applicability of this 
platform in detecting as low as 100 fg/ml PD-1, PD-L1, and LAG-3 spiked in serum. 
Moreover, by utilizing the multiplexing capacity of SERS, we successfully detect the all three 
immune-checkpoint protein from a complex serum sample when passed through a single 
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channel functionalized with respective NY-scFvs. We believe that this method will provide a 
significant improvement in the current clinical system for disease diagnosis and therapeutic 
monitoring. 
 
2. Materials and methods:  
2.1 Reagents: 
All reagents including antibodies, antigens were obtained from Sigma-Aldrich 
(Australia), Novusbio (Australia), R&D/Life Technologies (Burlington, ON), Thermo-Fisher 
Scientific (Australia), BBI Solutions system, Santa Cruz Biotech (Australia), Astral Scientific 
(Australia) and Invitrogen (Australia). All reagents and washing solutions used in the 
experiments were prepared using phosphate buffer saline (PBS, 1 mM, pH 7.4). Stock 
solutions of antibodies were diluted in PBS. Photoresists for fabrication (MicroChem, 
Murphys, CA) were used according to the manufacturer’s instruction. 
 
2.2 Preparation of SERS nanotags:  
The SERS nanotags were prepared by the same method as described by our previous 
studies(Kamil Reza et al. 2016). The gold nanoparticles were synthesized by citrate reduction 
of HAuCl4 as reported in literature.(Frens 1973) 
 The mixture of 2µL of 1.0 mM DSP 
(dithiobis succinimidyl propionate) in DMSO (dimethyl sulfoxide)  and Raman reporters 
(either 5 µL of 1 mM MBA (mercaptobenzoic acid), 10 µL of 1 mM DTNB ((5,5'-dithio-bis-
[2-nitrobenzoic acid]), 10 µL of 1 mM MMC (7-mercapto-4-methylcoumarin), in ethanol 
were incubated with 1.0 mL of AuNPs overnight to form a mixed thiol monolayer on  gold 
nanoparticle surface. Next, the colloid was centrifuged at 7600 rpm for 10 min to remove the 
residual reactants and then resuspended in 200 µL PBS buffer. Next, 2 µg either human anti-
PD-1, anti-PD-L1, anti-LAG-3, antibodies or isotype-matched immunoglobulin (IgG) control 
was added to the colloid with 0.5 h incubation time at room temperature. After that, the 
colloid was centrifuged at 7600 rpm at 4°C for 8 min to remove the free antibodies and 
resuspended in 200 µL of 0.1 % BSA for 0.5 h at room temperature which act as stabilising 
agent and also minimize the non-specific adsorption.  
2.3 Device fabrication:  
The nanoshearing chip was fabricated using standard photolithography procedures 
and PDMS channels were fabricated using soft lithography technique. The chip was 
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sandwiched between custom-built holders to introduce inlets and outlets for the reagents and 
sample run. The electrode patterns were designed in Layout Editor (L-Edit V15, Tanner 
Research Inc., CA) and printed on a chrome mask (5 in. × 5 in.) obtained from Qingyi 
Precision Mask-making (Shenzhen) Ltd., China. The device contains asymmetric planar 
microelectrode pairs within a long microchannel. The device contains five channels with 
individual inlet and outlet ports with each channel composed of 50 asymmetric planar 
electrode pairs (dimension of small and large electrode are 100 μm and 400 μm, separation 
between electrodes is 100 μm). Adjacent electrode pairs in each segment are separated by a 
distance of 150 μm. The small and large electrodes were connected to a larger gold pads to 
form the electrical connections. We have used 4-inch silicon wafers. Firstly, silicon dioxide 
(thickness, 200 nm) was deposited on silicon wafers (diameter, 100 mm; thickness, 1 mm; 
single-side polished) in an oxidation furnace to active passivation. The oxidised wafers were 
cleaned with acetone for 5 min under sonication, then rinsed with isopropyl alcohol and water 
for another 2 min and dried under nitrogen gas. To obtain a thick layer of resist, negative 
photoresist (AZnLOF 2070, MicroChem, Newton, MA) was spin coated (3000 rpm for 30 s) 
onto the wafer and soft baked at 110 °C for 6 min. Subsequently, these wafers were exposed 
to UV (280 mJ/cm2) using a mask aligner (EVG 620, EV Group GmbH, Austria) and 
development was done using AZ 726 developer (for 3 min), revealed the exposed patterns. 
Then the chips were rinsed with deionized (DI) water and dried under nitrogen gas. The 
metallic deposition (Ti (10 nm) and Au (200 nm)) onto chip was carried out using an electron 
beam (e-beam) evaporator (Temescal FC-2000) under high vacuum conditions followed by 
lift-off using ethanol exposing the patterned gold electrodes. Finally, the wafers were then 
diced (ADT 7100 wafer precision dicer) to obtain individual devices. 
The fabrication of microfluidic channels involves fabrication of an SU-8 master molds 
containing five independent microfluidic channels (width, w = 400 μm; height, h = 300 μm; 
length, l = 25 mm) with 1 mm diameter inlet and outlet ports. The fabrication of microfluidic 
channels on PDMS using the master molds were described here. Briefly, a thick layer of 
negative photoresist (SU-8 2150; MicroChem, Newton, MA) was spin coated (1800 rpm) 
onto a clean silicon wafer. The wafer was soft baked through a series of step changes in 
temperature (65 °C for 7 min, 95 °C for 60 min, 65 °C for 5 min). Subsequently, UV 
exposure (380 mJ/cm2) was followed by a post bake step (from 65 °C for 5 min, 95 °C for 20 
min, 65 °C for 3 min). To expose the fluidic channels, the wafers were developed in 
propylene glycol methyl ether acetate (PGMEA) for 45 min. To prepare the channels, PDMS 
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precursor was mixed with the curing agent (ratio 10:1; Sylgard 184 kit, Dow Corning, 
Midland, MI), degassed and allowed to cure in a conventional oven at 65 °C for 2 h. The 
cured PDMS replicas were removed from the molds and 1 mm holes were punched into 
PDMS at either ends of the channel to define the inlet and outlet ports (diameter, 1 mm). 
2.4 Generation of Nanoyeast-scFv: 
PD1, PDL-1 and LAG-3 whole yeast scFv and nanoyeast-scFv were produced as per 
the method detailed in this work (Li et al. 2018).  To check the specificity of NY-scFvs, we 
performed ELISA and found that all the target scFvs have high affinities towards the target 
antigen (supplementary figure S3). 
2.5 Multiplexed ac-EHD SERS Immunoassay:  
The fabricated chips were cleaned with acetone, ethanol and water and then dried with 
nitrogen gas and stored under sealed vacuum. The electrodes were then functionalized with 
GO following a method where a self-assembled monolayer of n-octadecyl mercaptan were 
used for absorption of the nanosheets.(Yang et al. 2010) In this way, we efficiently fabricated 
the graphene gold conjugate with a controllable surface coverage of GO. The GO 
functionalized device was then bonded to the PDMS containing the channels and the device 
was sandwiched between custom-built holders and fixed into a microfluidic platform. This 
step was then followed by HA antibody functionalization in separate channels of the device 
using standard EDC-NHS chemistry (EDC: 0.2 M; NHS: 0.05 M; mixing volume ratio of 1: 
1)(Ali et al. 2014). NY-scFv specific anti-PD-1 affinity agents (10 μg/mL) was immobilized 
with the use of a human influenza hemagglutinin (HA) antigen tag cloned into the 
recombinant scFv construct at room temperature for 1h leading to the immobilization of the 
antibody onto the GO functionalized gold surface. Thus, this assay uses anti-HA antibody to 
build immunoassays using yeast-scFvs selected to bind antigens of interest. Similarly, we 
also functionalized other channels with NY-scFv specific anti-PD-L1 and anti- LAG-3 
affinity agents at a concentration of 10 μg/mL using the same method. Afterwards, 1% BSA 
solution was passed through each of the channels to block the nonspecific adsorption. 
Supplementary figure S4 showed the schematic illustration of the GO ac-EHD immunoassay.    
  
Samples containing target proteins in serum were then driven under optimized ac-
EHD condition (f = 1.1 kHz and Vpp=120 mV).
 Upon capture, targets were detected using 
samples containing SERS-labelled antibody (anti-PD-1) and/or antibodies (anti-PDL-1, anti-
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LAG-3) driven through the capture domain under similar electric field condition. For clinical 
sample analysis, patient serum samples were obtained from Ventyx Wesley Research 
Institute Tissue Bank (Brisbane, Australia). Samples were collected and stored at -80ºC.  
 
2.6 SERS Measurement and data analysis: 
 
SERS spectra and images were recorded with a Witec alpha 300 R 
microspectrometer. The 632.8 nm line from a HeNe laser with a laser power of 4 mW on the 
sample was used for excitation of Raman scattering.(Zeman and Schatz 1987) The resolution 
for the Raman microspectrometer is 2 cm-1. The integration time of the SERS was 100 ms, 
with a mapping an area of 60 µm × 60 µm (60 pixel × 60 pixel) using a 20 × microscope 
objective. A silicon wafer was used for calibration of the system based on the Raman 
intensity of the first-order photon peak of silicon at ∼520 cm-1. We also performed 
background removal from the raw spectra was done using a Vancouver Raman Algorithm 
based on a fifth-order polynomial fitting method.(Zhao et al. 2007)  In order to reduce the 
error and improve the preciseness of the measurement, we scanned multiple positions on 
different electrodes in each channel. Each set of experiments were repeated thrice. Finally, 
average Raman intensities of the targets were obtained from these images from three different 
spectra for each sample (used the peak height to plot the intensity bar). 
 
3. Results and discussion 
3.1 Immune checkpoint platform 
To demonstrate the assay platform, we constructed an ac-EHD enabled microfluidic 
device (Figure 1, see experimental section for detail fabrication steps) containing asymmetric 
pairs of large and small electrodes (supplementary figure S1 and S2) using our previously 
developed method (Kamil Reza et al. 2016). The application of an alternating potential 
difference across large and small asymmetric electrode pair results in a non-uniform electric 
field that induces charges within the double layer of each electrode. The lateral variation in 
the total amount of induced double layer charges and spatial distribution of charges on the 
electrode surface, give rise to a stronger lateral forces on the large electrode resulting in a net 
fluid flow towards the large electrode. This surface shear force is unidirectional and generates 
within few nanometers of the sensing surface. Consequently, this surface shear force drags 
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the analytes in solution towards the flow and their mixing with the surface improves better 
interaction of antibody-antigen.  
 
Figure 1 shows the schematic illustration of the assay. The ac-EHD device was first 
functionalized with GO followed by the Hemagglutinin (HA) antibody using EDC/NHS 
chemistry (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide)/(N-hydroxysuccinimide). 
Next, PD-1, PDL1 and LAG-3 specific NY-scFvs which have HA antigen tag were attached 
to the functionalised HA antibody. The sample containing immune-checkpoint antigens were 
then injected into the different channels of the ac-EHD device consisting of an array of PD-1, 
PD-L1 and LAG-3 specific NY-scFv and GO functionalized gold electrode pairs. An ac-field 
was then applied to the GO coated gold electrode arrays which resulted in an EHD-induced 
fluid flow and generated delicate micro-mixing within few nanometres of the electrode 
surface (supplementary figure S3). Another channel was not functionalized with the NY-scFv 
to act as a negative control. Samples (20 μL) containing soluble immune checkpoints in 
serum were driven through functionalized devices using optimized ac-EHD conditions (f = 
1.1 kHz and Vpp = 120 mV) to facilitate specific target capture. Subsequently, the captured 
antigens were detected using three different SERS nanotags. SERS nanotags were 
synthesized using gold nanoparticles of size 60 nm conjugated with detection antibody and 
Raman reporters. The Raman reporters with their characteristic peaks are specific to the three 
target biomarkers. (e.g., MBA at 1074 cm-1 for PD-1 , DTNB at 1337 cm-1 for PD-L1 , and 
MMC at 1175 cm-1 for LAG-3) respectively. We utilized spatially resolved 
microspectroscopic SERS detection system and scanned multiple positions of each electrodes 
to acquire an average spectra of each biomarker. 
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Figure1: Schematic illustration of the SERS GO ac-EHD immunoassay for immmuno 
checkpoint blockade biomarkers. 
 
3.2 Initial investigation on GO and NY-scFv functionalised surface 
Graphene oxide has become very popular in biosensing due to its larger surface area 
which could allocate large number of antibodies directly into the sensor surface. In this way, 
we reduce the multiple functionalization steps of standard biotin-streptavidin procedure of 
antibody functionalization on any surface. To confirm the GO functionalization on gold 
surface, we carried out Raman studies of gold electrode and GO coated gold electrode (figure 
2 a). The two characteristics peaks of GO are D and G band confirms the functionalization of 
GO on gold electrode.  
Further, we carried out scanning electron microscopy (SEM), bright-field microscopy 
and differential pulse voltammetry (DPV) studies of the electrodes to show morphological 
differences of these electrodes.  As shown in figure 2( b and c), the modification of the (i) 
bare gold surface with (ii) graphene oxide caused a visible change in the bright field image (c 
(i-iii)) and increased the electrode surface roughness, as clearly indicated by the SEM images 
(d (i-ii)). The morphology change of the modified electrode is likely to be a result of the 
formation of graphene oxide layers on the gold surface. The conjugation with biomolecules 
could not be characterised by microscopy, thus we carried out an electrochemical study 
(supplementary figure S5). To monitor the stepwise electrode modification, we carried out 
electrochemical measurements using differential pulse voltammetry (DPV) with ferro/ferri-
cyanide redox couple. The successful electrode modification is indicated by a decrease in 
NYscFv
PD-L1PD-1 LAG-3
SERS with Ab
GO- Au electrode
HA Ab
LASER
Immune checkpoint 
markers
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DPV peak signal with every modification step.  Figure S5 (a) shows the stepwise 
functionalisation. Initially, the (i) DPV signal of the unmodified bare gold electrode was 
measured. Subsequently, the electrode was modified with layers of (ii) graphene oxide, (iii) 
HA antibody, (iv) PD-1 nanoyeast, and (v) PD-1 antigen. Each of these steps resulted in a 
DPV signal decrease suggesting the successful biosensor preparation. In figure S5 (b), a 
magnification of the inset in (a) with the DPV signals (ii-v) is shown for clarity.  
 
 
Figure 2:  (a) Raman spectra of gold electrodes and graphene oxide functionalised gold 
electrodes. [b (i-ii)] The SEM images of the bare gold electrode (Au) and gold electrode with 
graphene oxide coating (Au + GO).  [c (i-iii)] The microscopic images of (i) the gold 
electrode (Au) (insets show the magnification), (ii) gold with graphene oxide (Au + GO) and 
(iii) gold with graphene oxide,  HA ab and nanoyeast (PD-1) (Au + GO + antibodies). (d) 
Comparison between (i) graphene oxide (green bar) and (ii) biotin-streptavidin (blue bar) 
functionalized electrodes where the bar graphs show the average SERS intensity for the 
detection of HER2 protein using anti-HER-2 functionalised electrodes. The antibody 
functionalization time (FT) for graphene oxide ac-EHD assay is 1.5 hr and biotin-streptavidin 
ac-EHD assay is 4.5 hr respectively. Each data point represents the average of three separate 
trials (n = 3) and error bars represent the standard deviation of measurements within each 
experiment. 
 
To show the comparison in sensitivity of the GO and biotin streptavidin system, we 
functionalized two chips with HA antibody followed by NY-scFv on both devices and flew 
PD-1 antigen (1pg/mL ) under ac-EHD conditions (f= 1.1 kHz and Vpp =120 mV). In the first 
chip, HA antibody followed by NY-scFv was coated on to GO gold surface using EDC-NHS 
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chemistry, while in the second chip, same amount of HA antibody and NY-ScFv was coated 
onto gold surface using biotin-streptavidin process.  The Raman intensities obtained from GO 
ac-EHD (green bar) is higher than the biotin streptavidin ac-EHD gold surface (blue bar) with 
less antibody functionalization time (FT), providing a simple and  quicker way (figure 2d) of 
functionalization. 
 
 
3.2 Assay specificity study 
 
Figure 3 shows the detection specificity of the immune checkpoint assay. The 
corresponding false color SERS images are shown in supplementary figure S6. The 
specificity was investigated in human serum as a relevant example of a clinical sample. 
Aliquots of serum were spiked separately with 10 pg/mL immune checkpoint markers 
(positive control) or with 1 ng/mL non-target protein IgG (negative control). The human 
serum samples could contain 
trace concentrations of PD-1, PD-L1, and LAG-3. To assess for a detection bias due to the 
potential presence of these targets, the blank serum sample (without spiking) was also 
analysed as control. The samples were run through the device channels under an applied ac-
EHD field of f = 1.1 kHz and Vpp = 120 mV. As shown in figure 3, at a target concentration 
of 10 ng/mL, a strong SERS signal was obtained for all three immune checkpoint markers as 
can be seen from the SERS spectra and false-colour SERS images. The NY-scFv affinity 
reagents were crucial for successful target capture. In the absence of the NY-scFv (no scFv), 
PD-l, PD-L1, and LAG-3 could not be detected. All the negative control samples provided 
negligible signals. This data suggests that the immuno-capture was highly specific using the 
NY scFv integrated on the SERS ac-EHD device.  
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Figure 3.Assay specificity study for immune-checkpoint biomarkers in human serum. The 
SERS spectra and average SERS intensities are shown for  (a,b) PD-1 (peak at 1074 cm-1), 
(c,d) PD-L1 (peak at 1337 cm-1), and (e,f) LAG-3 (peak at 1174 cm-1). The samples were 
spiked with 10 pg/mL target antigen (black), target antigen without scFv (negative control, 
red), 1 ng/mL non-target IgG (negative control, blue), and blank serum (negative control, 
green).  Each data point in (b, d, and f) represents the average of three separate trials (n = 3) 
and error bars represent standard deviation (%RSD =<5% for n = 3) of measurements within 
each experiment.  
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3.3 Assay sensitivity and dynamic range 
To investigate the sensitivity and dynamic range of detection, serum samples 
containing designated concentrations of PD-1 (100 fg/mL to 1 ng/mL), PD-L1 (50 fg/mL to 
100 pg/mL), and LAG-3 (100 fg/mL to 1 ng/mL) were separately driven through the device 
under the applied ac-EHD field. Blank serum samples without target fortification (0 fg/mL) 
served as the negative controls. The left panel of Figure 4 shows the representative overlaid 
SERS spectra from the different concentrations of (a) PD-1, (c) PD-L1, and (e) LAG-3. As 
the target concentration increased, the intensity of the SERS signal increased proportionally. 
The right panel of Figure 4 shows the dynamic range for (b) PD-1, (d) PD-L1, and (f) LAG-3. 
For the dynamic range, the average peak Raman intensity (n=3) at 1074 cm-1 for PD-1, 1337 
cm-1 for PD-L1, and 1174 cm-1 for LAG-3 was plotted as a function of target concentration. 
The corresponding line relation between protein concentration and SERS intensity response 
curve for PD-1, PD-L1 and LAG-3 immune checkpoint marker proteins has been shown in 
supplementary figure S7(a-c). It shows the consistency in the functioning of device with 
coefficient of determination (R2) of PD-1 (0.992), PD-L1 (0.989) and LAG-3 (0.994), 
respectively. The assay covered a dynamic range of 2-4 orders of magnitude with detection 
limits as low as 50 fg/mL (for PD-L1). Furthermore, the assay was highly reproducible with 
errors < 3.65% RSD. These assay performance values are well suited for trace level detection 
of immune checkpoint markers. For instance, small changes in serum PD-L1 served as a 
predictive biomarker for the outcome of immune checkpoint blockade therapy in malignant 
melanoma and aggressive diffuse large B-Cell lymphoma (Rossille et al. 2014; Zhou et al. 
2017). However, the detection of these small changes could be a challenge for standard 
ELISA technology. This is because ELISA based technology is often limited by non-specific 
binding and long assay time (4 hours). This situation becomes aggravated for samples with 
very low target concentrations that can result false-positive signal. An advantage of our assay 
is that it used ac-EHD fluid flow to reduce the non-specific binding and minimise the chances 
for false positive results. Recently, Chou et al. reported a microfluidic platform with 
fluorescence readout which achieved highly sensitive detection of PD-L1 in the picomolar  
range (Chou et al. 2018). However, fluorescence based assays are limited by high background 
signal due to photo-bleaching and difficult for multiplexing due to spectral overlapping. On 
the contrary, our SERS-microfluidic assays provided highly sensitive detection with 
multiplexing capability which may address the limitations associated with current 
technologies.  
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Figure 4. Typical SERS spectra and dynamic range for PD-1 (a and b), PD-L1 (c and d) and 
LAG-3 (e and f).  The serum samples spiked with targets were run through the device under 
an ac-EHD field (f = 1.1 kHz and Vpp = 120mV). Control experiments were performed using 
blank serum samples (0 fg/mL). Each data point in (b), (d) & (f) represents the average of 
three separate trials (n = 3) and error bars represent standard deviation (%RSD <3.65% for n 
= 3) of the measurements. 
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Figure 5. (a) Typical SERS spectra of the parallel detection of PD-1, PD-L1, and LAG-3 in 
serum samples under ac-EHD field (f = 1.1 kHz and Vpp = 120mV). (b) false colour SERS 
images (scale bar is 10 µm) for PD-1 (red), PD-L1 (green) and LAG-3 (yellow) detection in 
the concentration range from 1 ng/mL to 100 fg/mL spiked in serum samples. Control 
experiments were performed using blank serum samples (0 fg/mL). 
 
3.4 Multiplex immune checkpoint detection  
To demonstrate the potential clinical application of our assay for parallel immune 
checkpoint detection, healthy serum samples fortified with the three immune checkpoint 
markers were analysed. To integrate the multiplexed detection, the channels of the device 
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were functionalised with anti-PD-1, anti-PD-L1, and anti-LAG-3 NY-scFvs. The fortified 
serum samples and control samples (blank serum without spiking) were then run through the 
device under the optimised ac-EHD conditions. After target capture, the detection was 
facilitated by incubation with the SERS nanotag solution under ac-EHD conditions. The 
SERS nanotag solution contained the anti-PD-1, anti-PD-Ll, and anti-LAG-3 antibodies 
conjugated SERS nanoparticle or barcodes for individual target identification. The 
representative SERS spectra and corresponding false-colour images are shown in Figure 5 (a) 
and (b), respectively. The narrow spectral width of the SERS reporter provided clear and 
multiplexed target identification without spectral overlap. The high detection sensitivity using 
SERS readout and reduction of non-specific adsorption due to ac-EHD were crucial for 
improving the assay performance. These were key two features in achieving detection limits 
of 100 fg/mL of protein from complex biological sample.  
Table 1: Comparison table of the most recent literatures working towards detection of 
immune checkpoints. 
 
To better understand the assay performance, we have compared our assay with 
previously developed method for immune checkpoint detection (Table 1) in terms sensitivity 
and dynamic detection range. We have compared the sensing parameters (detection limit and 
dynamic range) of the standard methods like ELISA (which can quantify the protein 
concentration) whereas IHC (Immunohistochemistry) and western blot methods were not 
Technique LOD Range Reference 
ELISA 
PD-1:0.117 ng/mL 
PD-L1:0.012 ng/mL 
LAG-3: N/A 
PD-1: 0.038–25.93 ng/mL) 
PD-L1: 0.007–0.632 ng/mL 
LAG-3: N/A 
(Kruger et al. 
2017) 
ELISA 
PD-L1: 130fM 
PD-1: N/A 
LAG-3: N/A 
PD-1: N/A 
PD-L1: 0.13–130 pM 
LAG-3: N/A 
(Chou et al. 
2018) 
ELISA 
PD-1:0.117 pg/mL 
PD-L1: 150 pg/mL 
LAG-3: N/A 
PD-1: 117–380 pg/mL) 
PD-L1: 150–850 pg/mL 
LAG-3: N/A 
(Li et al. 2016) 
ELISA 
PD-1: 20 pg/mL 
PD-L1: 3.9 pg/mL 
LAG-3: N/A 
PD-1: 20 – 517 pg/mL 
PD-L1: 3.9 - 398 pg/mL 
LAG-3: N/A 
(Yanaba et al. 
2016) 
SERS 
PD-1: 6.17 pg/mL 
PD-L1: 0.68 pg/mL 
EGFR: 69.86 pg/mL 
PD-1: 0.01 – 1.0 ng/mL 
PD-L1: 0.001 - 10 ng/mL 
EGFR: 0.1 - 1000 ng/mL 
(Li et al. 2018) 
SERS- 
ac-EHD (chip) 
PD-1: 100 fg/mL 
PD-L1: 50 fg/mL 
LAG-3: 100fg/mL 
PD-1: 100 fg/mL – 1ng/mL 
PD-L1:50 fg/mL – 100pg/mL 
LAG-3: 100 fg/mL – 1ng/mL 
Our work 
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considered as they are less sensitive and require high concentrations of protein. As shown in 
Table 1, our method has similar sensitivity like ELISA, however, has better dynamic range 
with low detection limit up to 100fg/mL. Moreover, our SERS ac-EHD method provides 
significant advantages over fluorescence based ELISA techniques due to greater multiplexing 
capabilities and photo-stability.      
 
Finally, we investigated the storage stability of our microfluidic device after 0 to 4 weeks of 
storage in a vacuum sealed box. We performed the assay for the detection of 1 ng/mL PD-1 
in each device stored for 0-4 weeks and measured the signal intensity. Supplementary figure 
S8 shows the SERS signal intensity as a function of storage time. The signal intensities were 
comparable over the tested storage period which demonstrates a good assay reproducibility as 
well as excellent storage stability.  
 
4. Conclusions 
In summary, we have developed an immune checkpoint biosensing strategy that 
combines SERS spectral encoding on an ac-EHD device for multiplexed and sensitive 
detection of soluble PD-1, PD-L1 and LAG-3. The significance of our research approach is 
the first demonstration of chip-based assay for the simultaneous detection of three immune 
checkpoint markers using SERS barcoding. We also explored the strategy of utilizing the 
novel recombinant NY-scFv affinity reagents for capturing target on the graphene oxide 
modified electrodes of the ac-EHD device.  The ac-EHD fluid flow actively stimulated target-
NY-scFv collisions and reduced the non-specific sensor binding.  Three SERS reporters were 
applied to unambiguously identify the captured immune checkpoint markers.  These features 
were key in enabling the multiplexed target detection in human serum samples with a 
sensitivity of 100 fg/mL. The immune checkpoint device could analyse five samples in 
parallel with a turn-around time of 45 min. Moreover, this microfluidic chip is rapid, 
multiplexable, highly sensitive and specific and can be used for the analysis of other 
clinically relevant biomarkers such as DNA/RNA, exosomes, circulating free DNA, etc. As a 
proof-of-concept study, this method is limited to the detection of three immune checkpoints 
at this stage. However, we believe that by increasing the multiplexing capability of the 
device, it would be possible to generate a holistic immune profile by monitoring a large 
number of immune checkpoint markers which will strongly support personalised cancer 
immunotherapy monitoring. 
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